Physician profile
David Hibbets
NPI 1205256153
$5,556.46
in general payments reported to CMS, 2019-2025
32 companies · $69.30 in 2025
The $69.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $1,103 · 2021: $1,478 · 2022: $1,001 · 2023: $933 · 2024: $354 · 2025: $69.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,052.01 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $936.05 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $872.64 | 2020-2025 | |
| Amgen INC. | $396.44 | 2019-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $273.69 | 2020-2023 | Trintellix |
| Pfizer INC. | $242.52 | 2019-2023 | |
| Glaxosmithkline, LLC. | $222.43 | 2021-2024 | Arexvy, Shingrix, Boostrix |
| Allergan, INC. | $208.61 | 2019-2020 | |
| Lilly USA, LLC | $189.02 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $174.85 | 2020-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.59 | 2020-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $116.28 | 2019-2021 | |
| Astellas Pharma US INC | $104.17 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $98.83 | 2021 | |
| Merck Sharp & Dohme LLC | $98.06 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $81.29 | 2019-2021 | |
| Biogen, INC. | $39.05 | 2021 | |
| Shire North American Group INC | $27.37 | 2019 | |
| Amarin Pharma, INC. | $27.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $26.25 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.21 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $23.96 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.41 | 2023 | |
| Lundbeck LLC | $18.59 | 2023 | Rexulti |
| Tris Pharma INC | $18.54 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.19 | 2023 | Rexulti |
| Corium, LLC | $16.43 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $15.61 | 2021 | |
| Boston Scientific Corporation | $15.31 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.40 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hibbets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.